Associate Editor

Rudolf Fluckiger, PhD

Instructor Harvard Medical School Boston
Brigham & Womens Hospital
Orthopaedic Research (Retired)
2587 Albany Street, West Hartford
CT 06117, USA



• (1973), dipl. natw, ETH-Zurich MS thesis Investigations on the reaction mechanism of saccharase-isomaltase” Supervisors A Cogoli & G Semenza
• (1977), PhD thesis Struktur, Funktion und Synthese von Hämoglobin A1c from University Basel; Supervisors: KH Winterhalter & MM Burger
• (1977), Licensure to teach chemistry at college level. Based on course in pedagogics and substitute teaching.
• (1988), venia docendi in Clinical Biochemistry
• (1978-1981), Postdoctoral stay at Childrens Hospital Boston with KH Gabbay for work on protein glycation, and Prof. PM Gallop for MS detection of boron-reprivatized polar compounds


• (1981-1987), Head of Diabetology laboratory at the ZLF, University Clinics Basel
In 2000, He joined Dr. Erdjan Salih at Childrens Hospital, Boston, to define the sites of post-translational modification of bone phosphoproteins and determined their biological role. This effort completed in 2003, he joined the Department of Orthopedic Research at Brigham and Womens Hospital to perform proteomic studies with SELDI-TOF MS on cell extracts of antigen presenting cells.
When he learned in 2000 of the finding of Prof. Ryser of a new potential drug target on CD4 that could be exploited for the development of novel HIV entry inhibitors, he started to seek funding for an HIV entry drug discovery effort which was so far unsuccessful. My goal is to have an commercial HIV entry inhibitor on the market that will allow HIV to get eradicated within my life-time.
Most recently he developed a therapeutic formulation that suppresses the pain of peripheral neuropathy by preventing the activation of Transient Receptor Potential Receptor (TRP) ion channels without side effects by treating the pain of our chemotherapy-induced peripheral neuropathy. This finding has wide ranging therapeutic applications. TRP-channels are involved in: All types of neuropathies (diabetic, uremic, heavy metal poisoning; Ischemic/reperfusion injuries (stroke/sports injuries like concussions, HIV patients on retroviral therapy); Autism; Epilepsy; Migraine; Asthma; Respiratory syndrome (in viral infections, like enterovirus D-68, MERS/SARS/Hanta virus); Post-traumatic stress; Tinnitus; Bone pain in orthopedic surgery; Alzheimers disease; Hypertension; Immunity enhanced conditions (diabetes, obesity ALS); Arthritic pain; Gastrointestinal mucosal disorders (Crohns, esophageal); Brain Function (dream activity); Longevity; Ocular (glaucoma, macular degeneration); Multiple sclerosis; Skin (fibromyalgia, rosacea); Cancer; Cystic fibrosis.

Research Interest

His research interests include: All types of neuropathies (diabetic, uremic, heavy metal poisoning, Ischemic/reperfusion injuries (stroke/sports injuries like concussions, HIV patients on retroviral therapy), Autism, Epilepsy, Migraine, Asthma, Respiratory syndrome (in viral infections, like enterovirus D-68, MERS/SARS/Hanta virus), Post-traumatic stress, Tinnitus, Bone pain in orthopedic surgery, Alzheimers disease, Hypertension, Immunity enhanced conditions (diabetes, obesity ALS), Arthritic pain, Gastrointestinal mucosal disorders (Crohns, esophageal), Brain Function (dream activity), Longevity, Ocular (glaucoma, macular degeneration), Multiple sclerosis, Skin (fibromyalgia, rosacea), Cancer, Cystic fibrosis.

Scientific Activities


• USGEB (Union of the Swiss Societies for Experimental Biology)
• Swiss Society for Biochemistry
• ETH Alumni Association
• 2004-American Chemical Association (2015; 10 Years)
• International Union of Pure and Applied Chemistry (IUPAC)


• (1979), Juvenile Diabetes Foundation (JDF) fellowship
• (1988), Venia docendi in Clinical Biochemistry, University Basel
• (1989), Milton Fund, University of Basel
• (1989), Roche Research Foundation Award, Hofmann-La Roche



1. Heisterbach PE, Todorov A, Flückiger R, Evans CH, Majewski M. Effect of BMP-12, TGF-ß1 and Autologous Conditioned Serum on Growth Factor Expression of Achilles Tendon Healing. Knee Surg Sports Traumatol Arthrose. 2012; 20: 1903-1910.
2. Majewski M, Ochsner PE, Liu F, Flückiger R, Evans CH. Accelerated Healing of the Rat Achilles Tendon in Response to Autologous Conditioned Serum. Am. J. Sports Med. 2009; 33(5): 381-394.
3. Curtin P, Mc Hugh KP, Zhou H-Y, et al. Modulation of Bone Resorption by Phosphorylation State of Bone Sialoprotein. Biochemistry. 2009; 48: 6876-6886.
4. Saad FA, Salih E, Wunderlich L, Flückiger R, Glimcher MJ. Prokaryotic Expression of Bone Sialoprotein and Identification of Casein Kinase II Phosphorylation Sites. BBRC. 2005; 333(2): 443-447. doi: 10.1016/j.bbrc.2005.05.124
5. Ryser HJ-P, Flückiger R. Progress in targeting HIV-1 entry. Drug Discovery Today. 2005; 10(16): 1085-1094. doi: 10.1016/S1359-6446(05)03550-6
6. Curtin P, Flückiger R, Goldhaber P, Salih E. Phosphorylation State - a Determinant of Extracellular Matrix Protein Function. Proceedings Irish Orthopaedic Association J Bone J Surg (Br). 2004.
7. Salih E, Flückiger R. Complete Topographical Distribution of Both the in vivo and in vitro Phosphorylation Sites of Bone Sialoprotein and their Biological Implications. J Biol Chem. 2004; 279(19): 19808-19815.
8. Curtin P, McHugh K, Flückiger R, Goldhaber P, Salih E. Role of Bone Sialoprotein Phosphorylation in Bone Resorption Using Calvarial Organ and Osteoclast Cultures. Chemistry and Biology of Mineralized Tissues. 2004; 73-76. doi: 10.1074/jbc.M310299200
9. Goldhaber P, Rabadjija L, Flückiger R, Salih E, Bernard G. Effect of Ascorbic Acid on Formation and Differentiation of Bone Cell Aggregates and their Ability to Heal Bone Resorption Defects by New Osteoid Formation in Neonatal Mouse Calvaria Grown in Serum-free Organ Culture. Biological Mechanisms of Tooth Movement and Craniofacial Adaptation. 2004; 179-195.
10. Curtin P, Wunderlich L, Flückiger R, Salih E. Alterations in Gene Expression Levels Due to Cancer-Bone Cell Interactions Studied by Comprehensive Gene Array Analysis. Transactions 50th Annual Orthopaedic Research Society Meeting. 2004.
11. Salih E, Wang J, Mah J, Flückiger R. Natural Variation in the Extent of Phosphorylation of Bone Phosphoproteins as a Function of in vivo New Bone Formation Induced by Demineralized Bone Matrix in Soft Tissue and Bony Environments. Biochem J. 2002; 364(Pt 2): 465-474.
12. Holmes DJ, Flückiger R, Austad SN. Comparative Biology of Aging in Birds: an Update. Experimental Gerontol. 2001; 36(4-6): 869-883. doi: 10.1016/S0531-5565(00)00247-3
13. Palakurthi SS, Flückiger R, Aktas H, et al. Inhibition of Translation Initiation Mediates the Anticancer Effect of the n-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid. Cancer Res. 2000; 60(11): 2919-2925.
14. Acosta J, Hettinga J, Flückiger R, et al. Molecular Basis for a Link Between Complement and the Vascular Complications of Diabetes. PNAS. 2000; 97(10): 5450-5455.
15. Palakurthi SS, Flückiger R, Aktas H, et al. Calcium Depletion, eIF2 alpha Phosphorylation and Cell Cycle Inhibition Mediate the Anti-Cancer Effect of Eicosapentaenoic Acid. Clinical Cancer Research. 1999; 5: 175.
16. Halperin JA, Acosta J, Hettinga J, Flückiger R. A novel role for complement in the vascular complocations of diabetes. Molecular Immuology. 1998; 35 (6-7).
17. Aktas H, Flückiger R, Acosta JA, Savage JM, Palakurthi SS, Halperin JA. Depletion of Intracellular Ca2+ Stores, Phosphorylation of eIF2alpha, and Sustained Inhibition of Translation Initiation Mediate the Anticancer Effects of Chlotrimazole. PNAS. 1998; 95(14): 8280-8285.
18. Halperin JA, Acosta J, Hettinga J, Flückiger R. A Novel Role for Complement in the Vascular Complications of Diabetes. Molecular Immunology. 1998; 35(6-7): 106.
19. Paz MA, Martin P, Flückiger R, Mah J, Gallop PM. The Catalysis of Redox Cycling by Pyrroloquinoline Quinone (PQQ), PQQ Derivatives, and Isomers and the Specificity of Inhibitors. Anal Biochem. 1996; 238(2): 145-149. doi: 10.1006/abio.1996.0267
20. Stites TE, Mah J, Flückiger R, Paz M, Gallop P, Rucker R. Dietary Deficiency of Pyrroloquinoline Quinone (PQQ) alters Mitochondrial Function in Young Mice. 1996.
21. Flückiger R, Strang CJ. Structural Requirements for Protein Glycation. Protein Science. 1995; 4(S2): 699S.
22. Flückiger R, Paz MA, Gallop PM. Redox-Cycling Detection of Dialyzable Pyrroloquinoline Quinone and Quinoproteins. Methods Enzymology. 1995; 258: 140-149.
23. Gallop PM, Paz MA, Flückiger R, Mah J, Bishop A, Stang PA. The PQQ: Anti PQQ System and the Regulation of Cytosolic and Mitochondrial Oxidative Process. Programme and Abstracts. 1994; 221.
24. Flückiger R, Paz M, Mah J, Bishop A, Gallop PM. Characterization of the Glycine-Dependent Redox-Cycling Activity in Animal Fluids and Tissues Using Specific Inhibitors and Activators: Evidence for Presence of PQQ. BBRC. 1993; 196(1): 61-68. doi: doi:10.1006/bbrc.1993.2216
25. Flückiger R. PQQ and Electron Transport in Mammalian systems. Nutr Rev. 1993; 51(1): 26-27. doi: 10.1111/j.1753-4887.1993.tb03053.x
26. Gallop PM, Paz MA, Flückiger R, Henson E. Is the Antioxidant, Anti-Inflammatory Putative New Vitamin, PQQ, Involved With Nitric Oxide in Bone Metabolism? Connect Tissue Res. 1993; 29(2): 153-161.
27. Austad SN, Flückiger R, Holmes DJ. Caloric Restriction Alters Oxidative Status but not Glycemia in the Opossum. Gerontologist. 1993.
28. Gallop PM, Paz MA, Flückiger R, Stang PJ, Zhdankin VV, Tykvinski RR. Highly Effective PQQ Inhibition by Alkynyl and Aryl Mono- and Diiodonium Salts. J Am Chem Soc. 1993; 115: 11702-11704. doi: 10.1021/ja00078a007
29. Mah J, Paz MA, Flückiger R, Gallop PM. Methoxatin (PQQ) Isolation from Rabbit and Rat Mitochondria: PQQ interacts with Thyroxin (T4) and mediates Electron Transport (et) process. FASEB J. 1993; 7(7): A53.
30. Paz MA, Mah J, Fluckiger R, Stang PJ, Gallop PM. Cofactor PQQ in Mitochondrial Complex 1, is the Target for Rotenone, MPP+, and Iodonium Compounds. ASMB/DBC-ACS Joint Meeting. Addendum LB80. 1993.
31. Gallop PM, Paz MA, Mah, J, Flückiger R. Aging, Mitochondria and Superoxide: Cofactor PQQ in NADH: CoQ Reductase (ND1), An mDNA-Encoded Subunit in Complex 1. J Gerontology. 1993; 33(11): 27.
32. Gallop PM, Paz MA, Flückiger R, Bishop A, Henson E. Is the Antioxidant, Anti-Inflammatory, Putative New Vitamin, and PQQ, Involved with Nitric Oxide in Bone Metabolism? Chemistry and Biology of Mineralized Tissues. 1992; 29-38.
33. Paz MA, Flückiger R, Gallop PM. The Biomedical Significance of PQQ. Principles and Applications of Quinoproteins. 1992; 381-393.
34. Flückiger R, Paz MA, Bergethon PR, Henson E, Gallop PM. Glycine Dependent Redox-Cycling and Other Methods for PQQ and Quinoprotein Detection. Principles and Applications of Quinoproteins. In: Davidson VL, ed. Marcel Dekker. 1992; 331-341.
35. Paz MA, Flückiger R, Boak A, Kagan HM, Gallop PM. Specific Detection of Quinoproteins by Redox-Cycling Staining. J Biol Chem. 1991; 266(2): 689-692.
36. Flückiger R, Paz MA, Bergethon PR, Goodman S, Henson E, Gallop PM. First Isolation of Methoxatin (PQQ) From Bovine Skim Milk and Other Mammalian Sources. FASEB J. 1991; 5(6): A1510.
37. Gallop, PM, Paz, MA, Flückiger R. Cofactor PQQ in Red Cells, Neutrophils and Biological Fluids, Catalyzes Dioxygen-Superoxide Interconversion. 1991.
38. Veldink GA, Boelens H, Maccarrone M, et al. Soybean Lipoxygenase-1 is not a Quinoprotein. FEBS Lett. 1990; 270(1-2): 135-138.
39. Flückiger R. Non-Enzymatic Protein Glycosylation in Diabetes Mellitus. Schweiz Rundsch Med Prax. 1990; 79(31-32): 907-908.
40. Paz MA, Flückiger R, Gallop PM. Redox-Cycling is a Property of PQQ But Not of Ascorbate. FEBS Lett. 1990; 264(2): 283-284.
41. Gallop PM, Paz MA, Flückiger R. The Biological Significance of Quinonoid Compounds in, on, and out of Proteins. Chemtracts. 1990; 1: 357-374.
42. Flückiger R, Sutedja HM, Gallop PM. Serum Protein Glycation and Serum Osteocalcin in Aging: a Study with ad Libitum Fed, Diet-Restricted and Diabetic Rats. Gerontologist. 1990; 30: 322A.
43. Paz MA, Flückiger R, Greenspan SL, Henson E, Gallop PM. Quinoproteins, PQQ and Quinonoid Compounds in Dioxygen Metabolism. Gerontologist. 1990; 30: 216A.
44. Gallop PM, Henson E, Paz MA, Greenspan SL, Flückiger R. Acid-Promoted Tautomeric Lactonization and Oxidation-Reduction of Pyrroloquinoline Quinone (PQQ). BBRC. 1989; 163(2): 755-763. doi: 10.1016/0006-291X(89)92287-0
45. Gallop PM, Paz MA, Flückiger R, Kagan HM. PQQ, the Elusive Coenzyme. Trends Biochem Sci. 1989; 14(8): 343-346.
46. Paz MA, Flückiger R, Henson E, Gallop PM. Direct and Amplified Redox-Cycling Measurements of PQQ in Quinoproteins and Biological Fluids: PQQ Peptides in Pronase Digests of DBH and DAO. PQQ and Quinoproteins. 1989; 131-143. doi: 10.1007/978-94-009-0957-1_20
47. Paz MA, Flückiger R, Torrelio BM, Gallop PM. Methoxatin (PQQ), Coenzyme for Copper-Dependent Amine and Mixed-Function Oxidation in Mammalian Tissues. Connective Tissue Research. 1989; 20: 251-257.
48. Flückiger R. Non-enzymatic glycosylation of proteins in diabetes mellitus: Implications for therapy monitoring, and developing diabetic late complications. Thieme Copythek. Thieme Verlag Stuttgart, New York. 1989.
49. Paz MA, Gallop PM, Torrelio BM, Flückiger R. The Amplified Detection of Free and Bound Methoxatin (PQQ) With Nitroblue Tetrazolium Redox Reactions: Insights into the PQQ-Locus. BBRC. 1988; 154(3): 1330-1337.
50. Flückiger R, Mortensen HB. Glycated haemoglobins. J Chromatogr. 1988; 429: 279-292.
51. Flückiger R, Woodtli T, Gallop PM. The Interaction of Amino groups with Pyrroloquinoline Quinone as Detected by the Reduction of Nitroblue Tetrazolium. BBRC. 1988; 153(1): 353-358. doi: 10.1016/S0006-291X(88)81230-0
52. Flückiger R. Glycosylated Haemoglobin in Cystic Fibrosis. Arch Dis Child. 1988; 63(2): 223-224.
53. Flückiger R, Ditzel J, Bucalossi A, Conti A, Piazza E, Berger W. Evidence for Modulation of Protein Glycation in vivo by Phosphate. 1988.
54. Flückiger R, Woodtli T, Berger W. Evaluation of the Fructosamine Test for the Measurement of Plasma Protein Glycation. Diabetologia. 1987; 30(8): 648-652.
55. Woodtli T, Ruch W, Flückiger R. HbA1c Determination in Capillary Blood. Schweiz Med Wochenschr. 1987; 117(2): 43-45.
56. Flückiger R, Woodtli T, Berger W. Influence of Protein Concentration on Fructosamine Values. Diabetologia. 1987.
57. Iberg N, Flückiger R. The Effect of Phosphate on the Kinetics of the Nonenzymatic Glycosylation (Glycation) Reaction. Experientia. 1987; 43:47.
58. Iberg N, Flückiger R. Nonenzymatic Glycosylation of Albumin in vivo: Identification of Multiple Glycosylated Sites. J Biol Chem. 1986; 261(29): 13542-13545.
59. Gregor I, Iberg N, Berger W, Flückiger R. Albumin-Directed antibodies in diabetes: demonstration of human serum albumin-directed IgM autoantibodies. Diabetologia. 1986; 29(8): 481-484. doi: 10.1007/BF00453497
60. Flückiger R, Pasquel M. HbA1c and HbA1 Determination in Diabetes Control. Schweiz Med Wochenschr. 1986; 116(3): 87-92.
61. Iberg N, Flückiger R. Nonenzymatic Glycosylation (Glycation) of Proteins: the Principal Sites of in Vitro Glycation of RNase A. Experientia. 1986; 42: 680.
62. Berger W, Lehner D, Flückiger R. Heterogeneity of Sorbitol Accumulation in Glucose Incubated Erythrocytes: a Possible Explanation for the Inherent Susceptibility for Neural Complications in Diabetic Subjects. Diabetologia. 1986; 29: 537A.
63. Flückiger R, Gregor I, Iberg N, Berger W. Albumin-Directed Antibodies in Diabetes: Demonstration of Human Serum Albumin-Directed IgM Autoantibodies. Diabetology. 1986; 29: 537A.
64. Flückiger R, Berger W. Monitoring of Metabolic Control in Diabetes Mellitus: Methodological and Clinical Aspects. Progress in Clinical Biochemical and Medicine. 1986; 3: 3: 1-27. doi: 10.1007/978-3-642-70998-2_1
65. Flückiger R. Das glykosylierte Hämoglobin. Internistische Welt. 1986; 2: 48-52.
66. Bock HA, Flückiger R, Berger W. Real and Artefactual Erythrocyte Swelling in Hyperglycaemia. Diabetology. 1985; 28(6): 335-338.
67. Flückiger R, Woodtli T. Effect of Temperature on Quantifying Glycated (Glycosylated) Hemoglobin by Cation-Exchange Chromatography. Clin Chem. 1985; 31: 114-117.
68. Flückiger R, Harmon WE. Assessment of Uremia by Carbamylated Hemoglobin: Interference of Monitoring Diabetic Control with Glycosylated Hemoglobin. In Advances in Non-Invasive Nephrology. 1985; 172-175.
69. Iberg N, Flückiger R. Nonenzymatic Protein Glycosylation: the Browning Reaction Proceeds without Intermolecular Cross-linking. Experience. 41: 783.
70. Flückiger R. Glycosylation of Lipoproteins: Chemistry and Biological Implications. Monographs Atherosclerosis. 1985; 13: 53-62.
71. Flückiger R, Henson E, Hess GM, Gallop PM. Mass Spectral and HPLC Analysis of Biological Compounds with Diphenylborinic Acid. Biomed Mass Spectrom. 1984; 11(12): 611-615.
72. Trüb B, Flückiger R, Winterhalter KH. Nonenzymatic Glycosylation of Basement Membrane Collagen in Diabetes Mellitus. Coll Relat Res. 1984; 4(4): 239-251.
73. Flückiger R, Gallop PM. Measurement of Nonenzymatic Protein Glycosylation. Methods Enzymology. 1984; 106: 77-87.
74. Flückiger R, Woodtli T, Berger W. Quantitation of Glycosylated Hemoglobin by Boronate Affinity Chromatography. Diabetes. 1984; 33(1): 73-76. doi: 10.2337/diab.33.1.73
75. Erne P, Mittelholzer E, Bürgisser E, Flückiger R, Bühler FR. Measurement of Receptor Induced Changes in Intracellular Free Calcium in Human Platelets. J Recept Res. 1984; 4(1-6): 587-604. doi: 10.3109/10799898409042575
76. Flückiger R. The Thiobarbitursäuremethode for HbA1c determination. Laboratory Medicine. 1984; 8: 120-121.
77. Bissé E, Berger W, Fluckiger R. Elimination von labilem HbA1c. Laboratoriums Medizin. 1984; 8: 122-123.
78. Flückiger R. Biochemical consequences of hyperglycemia. Medicine & Hygiene. 1984; 42: 3173-3176.
79. Berger W, Flückiger R. Determination of glycosylated hemoglobin HbA (1c) with commercial methods inferences from a comparison of methods. Swiss Aerztezeitung. 1984; 65: 1620-1622.
80. Flückiger R, Woodtli T, Berger W. Quantitation of Hemoglobin Glycosylation by Boronate Affinity Chromatography. Experientia. 1983; 39: 646.
81. Flückiger R, Woodtli T, Berger W. Absolute Quantitation of Hemoglobin Glycosylation by Boronate Affinity Chromatography. Diabetes. 1983; 32(S1): 80A.
82. Fluckiger R. The Thiobarbitursäuremethode for HbA1c determination. Aerztl Lab. 1983; 1: 19.
83. Bissé E, Flückiger R, Berger W. Kinetik der HbA1-Bildung unter Verschiedenen Glukosekonzentrationen. Aerztl Lab. 1983; 1: 21.
84. Bissé E, Berger W, Flückiger R. Studies on the formation and elimination of the aldimine form of glycohemoglobin. Aerztl Lab. 1983; 1: 22.
85. Flückiger R. Assessment of Uremia by Hemoglobin Carbamylation. In: Non-Invasive Diagnosis of Kidney Disease. In: Lubec G, ed. 1983; 3: 96-102.
86. Nissen C, Moser Y, Bendi Y, et al. Paroxysmal nocturnal Haemoglobinuraemie-a purely cellular Erythrozytendeffekt ? Schweiz Med Wschr. 1983; 113(40): 1481.
87. Sosenko JM, Kitzmiller JL, Flückiger R, Loo SW, Younger DM, Gabbay KH. Umbilical Cord Glycosylated Hemoglobin in Infants of Diabetic Mothers: Relationships to Neonatal Hypoglycemia, Macrosomia, and Cord Serum C-Peptide. Diabetes Care. 1982; 5(6): 566-570.
88. Bissé E, Berger W, Flückiger R. Quantitation of Glycosylated Hemoglobin. Elimination of Labile Glycohemoglobin During Sample Hemolysis at pH 5. Diabetes. 1982; 31(7): 630-633. doi: 10.2337/diab.31.7.630
89. Flückiger R, Berger W. Glycosylated hemoglobin in diabetes monitoring. Diabetes information. 2: 2-5.
90. Harmon W, Flückiger R, Arnout MA, Meier W, Gabbay KH. The Extent of Hemoglobin (Hb) Carbamylation is Correlated with Long-Term Time-Averaged Concentration (TAC) of Urea. Kidney International. 1982; 21: 151.
91. Gallop PM, Flückiger R, Hanneken A, Mininsohn MM, Gabbay KH. Chemical Quantitation of Hemoglobin Glycosylation: Fluorometric Detection of Formaldehyde Released upon Periodate Oxidation of Glycoglobin. Anal Biochem. 1981; 117(2): 427-432. doi: 10.1016/0003-2697(81)90802-2
92. Flückiger R, Harmon W, Meier W, Loo S, Gabbay KH. Hemoglobin Carbamylation in Uremia. N Engl J Med. 1981; 304(14): 823-827. doi: 10.1056/NEJM198104023041406
93. Gabbay KH, Flückiger R. Clinical Significance of Glycosylated Hemoglobin. Diabetes Mellitus. In: Rifkin V, Raskin V, eds. 1981; 241-246.
94. Flückiger R, Gallop PM, Gabbay KH. Posttranslational Modifications of Hemoglobin. Biological Mechanisms of Ageing. 1981; 81(2149): 400-405.
95. Sosenko JM, Flückiger R, Platt OS, Gabbay KH. Glycosylation of Variant Hemoglobins in Normal and Diabetic Subjects. Diabetes Care. 1980; 3(5): 590-593.
96. Gabbay KH, Sosenko JM, Banuchi GA, Mininsohn MJ, Flückiger R. Glycosylated Hemoglobins: (1980) Increased Glycosylation of Hemoglobin A in Diabetic Patients.Diabetes. 1979; 28(4): 337.
97. Flückiger R, Winterhalter KH. Glycosylated Hemoglobins. Biochemical And Clinical Aspects of Hemoglobin Abnormalities. 1978; 205-214.
98. Flückiger R. Structure, Function and Synthesis of Hemoglobin A1c. Inaugural Dissertation, University of Basel. 1978.
99. Flückiger R & Winterhalter KH. Glycosylated Hemoglobins. Proceedings Pingree Park Abnormal Hemoglobin Conference. 1977.
100. Flückiger R, Winterhalter KH. Glycosylated Hb in Whole Blood: Rapid Quantitation and Functional Properties. Experientia. 1977; 33: 791.
101. Flückiger R, Winterhalter KH. Haemoglobin A1c, a Reliable Index of Diabetic Control. Diabetologia. 1977; 13: 39.
102. Flückiger R, Winterhalter KH. In vitro Synthesis of Haemoglobin AIc. FEBS Lett. 1976; 71(2): 356-360.
103. Flückiger R, Winterhalter KH. Chemical Nature of Hemoglobin A1c, the Minor Haemoglobin Massively Increased in Diabetes Mellitus. Experience. 1976; 32: 767.
104. Flückiger R, Winterhalter KH. Synthesis of HbA1c in vitro. Proceedings 16th Int. Congress of Hematology. 1976; 53-54.
105. Winterhalter KH, Flückiger R, DiIorio E. Protoporphyrin Globin in Erythropoietic Protoporphyrinaemia. Proceedings of the 9th Annual Meeting of the European Society for Clinical Investigation. 1975; 70.
106. Flückiger R. Studies on the reaction mechanism of isomaltase. ETH Zurich.1973.
107. Flückiger R. Nephrology should trail blaze the end of chronic disease. Nephrol Open J. 2016; 1(3): 49-50. doi: 10.17140/NPOJ-1-109